

AMBS and HARRIS  
Application No.: 09/830,977  
Page 3

PATENT

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"


If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Annette S. Parent  
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
ASP:dmw  
SF 1403000 v1



PATENT

Application No.: 09/830,977  
Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 17 of page 47 has been amended as follows:

Northern blotting: Total cellular RNA was prepared with the RNeasy™ kit (QIAGEN). 30-50 µg of RNA were ~~were~~ resolved on a 1.2% agarose gel containing 6.3% formaldehyde, transferred to a Hybond™-N nylon membrane (Amersham) and hybridized with a <sup>32</sup>P-labeled cDNA probe containing either the full-length human NOS2 sequence (Geller *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 90:3491-3495 (1993)) or 522 bp of the human VEGF sequence common for all known VEGF isoforms. The VEGF cDNA was generated by RT-PCR (Advantage<sup>®</sup>RT-for-PCR kit, Clontech) using RNA from HCT-116 human colon carcinoma cells. PCR: 32 cycles, 1 min at 58°C, at 72°C and at 94°C using Taq polymerase (Perkin Elmer); cDNA primers: 5'-GCCTCCGAAACCATGAACCTTC-3' (SEQ ID NO:1), 5'-CGAGTCTGTGTTTGCAGGAAC-3' (SEQ ID NO:2).